Skip to main navigation Skip to search Skip to main content

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

  • Daniel L. Hertz
  • , Markus Joerger*
  • , Yung Jue Bang
  • , Ron H. Mathijssen
  • , Caicun Zhou
  • , Li Zhang
  • , David Gandara
  • , Michael Stahl
  • , Bradley J. Monk
  • , Ulrich Jaehde
  • , Jan H. Beumer*
  • *Corresponding author for this work
  • University of Michigan, Ann Arbor
  • Cantonal Hospital St. Gallen
  • Seoul National University College of Medicine
  • Tongji University
  • Sun Yat-Sen University
  • University of California at Davis
  • Kliniken Essen-Mitte
  • University of Arizona
  • University of Bonn
  • University of Pittsburgh Cancer Institute
  • University of Pittsburgh
  • University of Pittsburgh School of Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

29 Citations (Scopus)
42 Downloads (Pure)

Abstract

Paclitaxel, one of the most frequently used anticancer drugs, is dosed by body surface area, which leads to substantial inter-individual variability in systemic drug exposure. We evaluated clinical evidence regarding the scientific rationale and clinical benefit of individualized paclitaxel dosing based on measured systemic concentrations, known as therapeutic drug monitoring (TDM). In retrospective studies, higher systemic exposure is associated with greater toxicity and efficacy of paclitaxel treatment across several disease types and dosing regimens. In prospective trials, TDM reduces variability in systemic exposure, and has been demonstrated to reduce toxicity while retaining treatment efficacy for 3-weekly dosing in patients with advanced non-small cell lung cancer. Despite the demonstrated benefits of paclitaxel TDM, clinical adoption has been limited due to the challenges with sample collection and analysis. Based on our review, we strongly recommend TDM for patients receiving every 3-week paclitaxel in combination with a platinum agent for advanced NSCLC, due to the prospectively demonstrated clinical benefits, and find moderate evidence to recommend TDM for paclitaxel 3-hour infusions for other tumor types and preliminary evidence suggesting potential usefulness for paclitaxel administered by 1-hour infusions.

Original languageEnglish
Article number114024
JournalEuropean Journal of Cancer
Volume202
DOIs
Publication statusPublished - May 2024

Bibliographical note

Publisher Copyright:
© 2024 Elsevier Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations'. Together they form a unique fingerprint.

Cite this